{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-09-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "0904-7469",
      "generic_name": "Bupropion Hydrochloride",
      "labeler_name": "Major Pharmaceuticals",
      "brand_name": "Bupropion Hydrochloride XL",
      "brand_name_suffix": "XL",
      "active_ingredients": [
        {
          "name": "BUPROPION HYDROCHLORIDE",
          "strength": "300 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "0904-7469-04",
          "description": "30 BLISTER PACK in 1 CARTON (0904-7469-04)  / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK",
          "marketing_start_date": "20241007",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {
        "manufacturer_name": [
          "Major Pharmaceuticals"
        ],
        "rxcui": [
          "993541",
          "993557"
        ],
        "spl_set_id": [
          "aa3d3e5b-74a3-47f6-b9aa-d6e248e950e5"
        ],
        "unii": [
          "ZG7E5POY8O"
        ]
      },
      "marketing_category": "ANDA",
      "dosage_form": "TABLET, EXTENDED RELEASE",
      "spl_id": "6c37a396-f770-4ee5-9693-b65e0d8a9b97",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20241007",
      "product_id": "0904-7469_6c37a396-f770-4ee5-9693-b65e0d8a9b97",
      "application_number": "ANDA090693",
      "brand_name_base": "Bupropion Hydrochloride",
      "pharm_class": [
        "Aminoketone [EPC]",
        "Dopamine Uptake Inhibitors [MoA]",
        "Increased Dopamine Activity [PE]",
        "Increased Norepinephrine Activity [PE]",
        "Norepinephrine Uptake Inhibitors [MoA]"
      ]
    }
  ]
}